Is Arvinas, Inc. (ARVN) Overvalued?
We dive into why Arvinas, Inc. (ARVN) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Commentary & Analysis
Why Arvinas, Inc.’s (ARVN) Stock Is Down 7.61%
As of Wednesday, August 05, Arvinas, Inc.’s ARVN share price has dipped by 7.61%, which has investors questioning if this is right time to buy.Michael Rose
Why Arvinas, Inc.’s (ARVN) Stock Is Up 14.45%
As of Tuesday, August 04, Arvinas, Inc.’s ARVN share price has surged by 14.45%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Arvinas, Inc.’s (ARVN) Stock Is Up 17.00%
As of Tuesday, August 04, Arvinas, Inc.’s ARVN share price has surged by 17.00%, which has investors questioning if this is right time to sell.Tudor Pop
What You Need to Know About Arvinas, Inc.'s Q3 Earnings
Arvinas, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (ARVN) missed or beat analyst's expectations.Tudor Pop
Financial Summary
| Share Statistics | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $590.1 | $618.0 | 38% |
|
| Shares Out (Mil) | 65.7 | 44.8 | 54% |
|
| Institutional Ownership | 96.9% | 85.3% | 72% |
|
| Float (Mil) | 56.8 | 47.4 | 50% |
|
| Beta | 1.74 | 0.70 | 88% |
|
| Avg Daily Volume (000s) | 662 | 390 | 62% |
|
| Price Change (52-week) |
26.4% | 68.6% | 66% |
|
| Growth | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 58.9% | 6.7% | 97% |
|
| Net Income (5yr) | 7.5% | (1.6%) | 51% |
|
| EPS (5yr) | 17.7% | 14.9% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.2%) | (14.9%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 11 | |
| Current EPS | ($0.927) | ($0.068) | ($3.072) | |
| Month Ago EPS | ($0.804) | ($2.852) | ($3.333) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.827) | ($2.897) | ($3.329) | |
| Year/Year Chg | (135.9%) | (94.0%) | 121.4% | |
| Financials | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $317 | $291 | 36% |
|
| Net Income (TTM) (Mil) | $9 | ($11) | 45% |
|
| EPS (TTM) | $0.139 | ($0.700) | 44% |
|
| Operating Cash Flow (TTM) (Mil) | ($207) | ($6) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($21) | $5 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $6 | 26% |
|
| Enterprise Value (Q1) (Mil) | ($11) | $450 | 2% |
|
| Valuation | ARVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.05 | 2.78 | 24% |
|
| P/E | 67.4 | 17.4 | 89% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 3.8 | 1.1 | 83% |
|
| Ratios | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 97.2% | 67.0% | 96% |
|
| Net Margin | 2.9% | (2.3%) | 41% |
|
| ROA | 1.2% | (22.4%) | 49% |
|
| ROE | 1.6% | (20.2%) | 38% |
|
| Liabilities to Assets | 16.7% | 32.2% | 11% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
